Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase IIb study begins of Azixa as front-line treatment for glioblastoma multiforme

Dec. 27, 2010

Cyclacel's cell cycle inhibitor CYC-065 suppresses growth of MM cell in vitro

Dec. 27, 2010

Cylene Pharmaceuticals divulges novel inhibitors of protein kinases

Dec. 27, 2010

TetraLogic Pharmaceuticals claims new inhibitors of apoptosis protein inhibitors

Dec. 27, 2010

Threshold reports phase I data for TH-302 in patients with advanced leukemia

Dec. 24, 2010

Combination of AZD-0530 and anastrozole shows promise in hormone receptor-positive breast cancer

Dec. 24, 2010

Sunesis begins phase III vosaroxin trial in acute myeloid leukemia

Dec. 24, 2010

Promising phase I data on CAL-101 in hematological malignancies disclosed

Dec. 24, 2010

CHMP recommends approval of Teysuno for treatment of advanced gastric cancer

Dec. 23, 2010

Oncothyreon begins phase I/II trial of PX-866/cetuximab combination

Dec. 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...